REAL CLINICAL PRACTICE RESULTS OF INTERLEUKIN23 BLOCKERS IN REFRACTORY PSORIASIS

M.D. GIL-SIERRA[1], M.D.P. BRICEÑO-CASADO[2], C. MORENO-RAMOS[3], E. RIOS-SANCHEZ[3], J.M. BORRERO-RUBIO[3]
[1]HOSPITAL UNIVERSITARIO PUERTO REAL, PHARMACY, PUERTO REAL, SPAIN
[2]HOSPITAL GENERAL NUESTRA SEÑORA DEL PRADO, PHARMACY, PUERTO REAL, SPAIN
[3]HOSPITAL UNIVERSITARIO DE PUERTO REAL, PHARMACY, PUERTO REAL, SPAIN

4. Historical research | **5PSQ-062**

BACKGROUND

Risankizumab and **guselkumab** are anti-interleukin-23 monoclonal antibodies used for **moderate to severe psoriasis** (msPs).

AIM

To evaluate the **effectiveness** and **safety** of **interleukin-23 blockers** in patients with msPs refractory to other biological agents **in clinical practice**.

MATERIAL AND METHODS

Descriptive retrospective study from **November 2017** to **September 2021**

Patients → **msPs** receiving **risankizumab** or **guselkumab** and previously treated with other biological agents

DATA: Electronic medical history and Farmatools® application

- Age
- Sex
- Previous biological treatments
- Anti-interleukin-23 monoclonal antibodies used
- Therapy duration
- Baseline Psoriasis Area and Severity Index (PASI)

Effectiveness

Effectiveness endpoint: PASI90 (≥90% reduction from baseline PASI) at 16 and 52 weeks

Safety

Endpoints: adverse events (AE) and treatment withdrawals associated with AE.

Schemes

Guselkumab: 100 mg by subcutaneous administration at weeks 0 and 4, followed by a maintenance dose of 100 mg every 8 weeks.
Risankizumab: 150 mg by subcutaneous injection at weeks 0 and 4, followed by a maintenance dose of 150 mg every 12 weeks.

RESULTS

- **Patients**: 37 patients
- **Sex:** 40% of patients were female and 60% were male
- **Age:** median of 48 (28-82) years.
- **Previous biological treatments:** median number of previous therapies was 4 (1-6).
- **Most frequent previous biologic treatments:**
  - → 94.3% adalimumab
  - → 88.6% etanercept
  - → 77.1% ustekinumab
- **Duration of interleukin-23 blocker treatment:** median of 12 (1-31) months.
- **Regimens of interleukin-23 blockers :**
  - → 65.7% guselkumab
  - → 34.3% risankizumab
- **Baseline PASI:** Median of baseline PASI values was 13 (7-21)

Safety:
→ AE: 17.1% of patients.
→ Total of AE: 14. Distribution: 5 hypercholesterolemia, 3 hypertriglycerdidemia, 2 hypertransaminemia, 2 hyperglycemia, 1 albuminuria and 1 non-alcoholic fatty liver.
→ No treatment withdrawals associated with AE were observed.



CONCLUSION

The **effectiveness** of **anti-interleukin-23 antibodies increased over time** in our patients with msPs refractory to other biological agents**.**

Almost three-quarters of patients reached **PASI90 at week 52**. **Safety** was **acceptable**, without treatment withdrawals.

CONTACT DATA

E-mail: mangilsie@yahoo.com